drugset / Trial / NCT00429481

Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants

NCT00429481

Phase 2 Completed 2464 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

To assess the efficacy, immune response and safety of 2 doses of HRV vaccine (at different concentrations) in healthy infants aged approximately 3 months previously uninfected with human rotavirus.

Timeline

Start
2001-01
Primary completion
2003-04
Completion
2003-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotarix Vaccine Oral